Metadon 25 AM Tablet PR is a combination antihypertensive medication containing Amlodipine 5 mg and Metoprolol Succinate 25 mg. Amlodipine is a long-acting dihydropyridine calcium channel blocker that inhibits calcium ion influx into vascular smooth muscle and cardiac muscle, resulting in vasodilation and decreased peripheral resistance, thereby lowering blood pressure. Metoprolol Succinate is a selective beta-1 adrenergic receptor blocker that reduces heart rate, myocardial contractility, and cardiac output, contributing to blood pressure reduction and improved cardiac function. This fixed-dose combination is indicated for the management of essential hypertension, providing enhanced blood pressure control through complementary mechanisms of action. It may also be used in patients requiring beta-blockade with concomitant calcium channel blockade for optimal cardiovascular risk reduction. The extended-release formulation of Metoprolol Succinate ensures sustained beta-blockade over 24 hours, allowing once-daily dosing and improved patient compliance. Metadon 25 AM Tablet PR should be used under medical supervision, with dosage adjustments based on clinical response and tolerability. Caution is advised in patients with bradycardia, heart block, or severe hepatic impairment. Common adverse effects include dizziness, fatigue, and peripheral edema. Regular monitoring of blood pressure and heart rate is recommended during therapy.